Cargando…

Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays

Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Hönemann, Mario, Lück, Christian, Maier, Melanie, Pietsch, Corinna, Dietze, Nadine, Berthold, Tom, Encalada, Marco Vinicio Narvaez, Grünewald, Thomas, Neumeister, Volker, Dalpke, Alexander, Liebert, Uwe Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983330/
https://www.ncbi.nlm.nih.gov/pubmed/33930691
http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382
_version_ 1783667883570626560
author Hönemann, Mario
Lück, Christian
Maier, Melanie
Pietsch, Corinna
Dietze, Nadine
Berthold, Tom
Encalada, Marco Vinicio Narvaez
Grünewald, Thomas
Neumeister, Volker
Dalpke, Alexander
Liebert, Uwe Gerd
author_facet Hönemann, Mario
Lück, Christian
Maier, Melanie
Pietsch, Corinna
Dietze, Nadine
Berthold, Tom
Encalada, Marco Vinicio Narvaez
Grünewald, Thomas
Neumeister, Volker
Dalpke, Alexander
Liebert, Uwe Gerd
author_sort Hönemann, Mario
collection PubMed
description Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction panel included samples of patients with recent infection with either of the endemic Coronaviruses 229E, NL63, HKU1, or OC43. Additionally, samples with high antibody levels against influenza virus, adenovirus, and during acute EBV infection were included. Previous infection with endemic coronaviruses caused a significant amount of cross-reactivity in two of the assays. In contrast, the confidence intervals for the assays of Abbott, DiaSorin, Euroimmun and Roche encompassed the value of 98% for samples with a previous endemic HCoV infection. For all assays, sensitivities were between 91.3% and 98.8%. Assay performance was independent of the usage of either nucleocapsid or spike proteins.
format Online
Article
Text
id pubmed-7983330
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79833302021-03-23 Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays Hönemann, Mario Lück, Christian Maier, Melanie Pietsch, Corinna Dietze, Nadine Berthold, Tom Encalada, Marco Vinicio Narvaez Grünewald, Thomas Neumeister, Volker Dalpke, Alexander Liebert, Uwe Gerd Diagn Microbiol Infect Dis Article Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction panel included samples of patients with recent infection with either of the endemic Coronaviruses 229E, NL63, HKU1, or OC43. Additionally, samples with high antibody levels against influenza virus, adenovirus, and during acute EBV infection were included. Previous infection with endemic coronaviruses caused a significant amount of cross-reactivity in two of the assays. In contrast, the confidence intervals for the assays of Abbott, DiaSorin, Euroimmun and Roche encompassed the value of 98% for samples with a previous endemic HCoV infection. For all assays, sensitivities were between 91.3% and 98.8%. Assay performance was independent of the usage of either nucleocapsid or spike proteins. Elsevier Inc. 2021-08 2021-03-22 /pmc/articles/PMC7983330/ /pubmed/33930691 http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hönemann, Mario
Lück, Christian
Maier, Melanie
Pietsch, Corinna
Dietze, Nadine
Berthold, Tom
Encalada, Marco Vinicio Narvaez
Grünewald, Thomas
Neumeister, Volker
Dalpke, Alexander
Liebert, Uwe Gerd
Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title_full Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title_fullStr Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title_full_unstemmed Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title_short Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
title_sort comprehensive evaluation of eight commercial sars-cov-2 igg assays
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983330/
https://www.ncbi.nlm.nih.gov/pubmed/33930691
http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382
work_keys_str_mv AT honemannmario comprehensiveevaluationofeightcommercialsarscov2iggassays
AT luckchristian comprehensiveevaluationofeightcommercialsarscov2iggassays
AT maiermelanie comprehensiveevaluationofeightcommercialsarscov2iggassays
AT pietschcorinna comprehensiveevaluationofeightcommercialsarscov2iggassays
AT dietzenadine comprehensiveevaluationofeightcommercialsarscov2iggassays
AT bertholdtom comprehensiveevaluationofeightcommercialsarscov2iggassays
AT encaladamarcovinicionarvaez comprehensiveevaluationofeightcommercialsarscov2iggassays
AT grunewaldthomas comprehensiveevaluationofeightcommercialsarscov2iggassays
AT neumeistervolker comprehensiveevaluationofeightcommercialsarscov2iggassays
AT dalpkealexander comprehensiveevaluationofeightcommercialsarscov2iggassays
AT liebertuwegerd comprehensiveevaluationofeightcommercialsarscov2iggassays